viewHarvard Bioscience

Harvard Bioscience sees second-quarter revenue beat expectations, reiterates strong guidance

The medical instruments company posted revenue of $29.6 million, narrowly ahead of Street expectations of $29.3 million

Harvard Bioscience building
The quarterly results for the three months ended June marked the last period under the leadership of former CEO Jeff Duchemin

Harvard Bioscience Inc (NASDAQ:HBIO) stock soared Friday after the company on Thursday posted second-quarter results that beat expectations and reaffirmed its promising guidance.

The medical instruments company posted quarterly revenue of $29.6 million, a 6% year-on-year dip from the $31.6 million reported a year earlier but narrowly ahead of Street expectations for $29.3 million.

Earnings came in at $0.04 per share, down from $0.07 in the year-ago quarter and right in line with consensus estimates.

Drawing investors ,ain attention, however, was the Holliston, Massachusetts company’s full-year guidance. Harvard Bioscience reiterated its projection for earnings of between $0.19 and $0.20 per share on revenue of between $119 and $122 million.

Analysts were looking toward the lower end of that range, projecting $0.19 per share on revenue of $119.5 million.

READ: Acasti Pharma to investors: We're not planning a capital raise

The company’s stock rocketed nearly 40% higher Friday afternoon.

The quarterly results for the three months ended June marked the last period under the leadership of former CEO Jeff Duchemin. On July 8, Chairman James Green was named president and CEO of the company.

“Although our performance for the quarter was in the range expected, we can do better,” Green said in a statement on thecompany's website

“Our focus is to improve the underlying performance of our business, including revenue and gross margin growth, lowering operating expenses and reducing interest expense. We are putting acquisitions on hold for the near-term while we finish consolidating and integrating our previous acquisitions and demonstrate we can efficiently operate our business on an organic basis,” he added.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Harvard Bioscience

Price: 3.24 USD

Market: NASDAQ
Market Cap: $123.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: TRACON Pharmaceuticals reveals its low-cost drug development...

TRACON Pharmaceuticals (NASDAQ:TCON) CEO Charles Theuer tells Proactive the biotechnology company ended 2019 with cash, cash equivalents and short-term investments of $16.4 million. Theuer explains despite engaging in five different clinical trials, three of the five company's clinical trials...

18 hours, 17 minutes ago

2 min read